Paper Details

  1. Home
  2. Paper Details

Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group.

Author: BahnsonR, BrosmanS, MiddletonR, SteinbergG, WajsmanZ, WehleM

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Valrubicin is effective in treating bladder cancer in patients who failed or relapsed after BCG therapy. The treatment was safe and resulted in good anthracycline recovery in urine samples.
Paper Details　
Original Abstract of the Article :
We assess the efficacy and safety of intravesical valrubicin for the treatment of carcinoma in situ in patients with failure or recurrence after bacillus Calmette-Guerin (BCG) and who otherwise would have undergone cystectomy. Total anthracycline recovery in urine samples obtained within 24 hours of...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/10687972

データ提供：米国国立医学図書館（NLM）

Valrubicin: A Treatment Option for BCG-Refractory Carcinoma in Situ of the Bladder

Carcinoma in situ (CIS) of the bladder, a type of cancer that affects the lining of the bladder, can be a difficult condition to treat. Bacillus Calmette-Guerin (BCG), a type of immunotherapy, is often the first-line treatment for CIS. However, some patients experience recurrence or fail to respond to BCG therapy. This study investigates the efficacy and safety of valrubicin, a chemotherapy drug, for treating BCG-refractory CIS of the bladder.

Valrubicin: A Promising Alternative for BCG-Refractory CIS

The study demonstrates the efficacy and safety of valrubicin for treating BCG-refractory CIS. Valrubicin, administered intravesically (directly into the bladder), was found to be an effective treatment option for patients who had failed or experienced recurrence after BCG therapy. The study provides valuable insights into the potential of valrubicin as a viable alternative for managing this challenging condition.

Navigating the Desert of Bladder Cancer Treatment: Seeking New Solutions

The study underscores the importance of exploring alternative treatment options for bladder cancer, particularly for patients who do not respond to standard therapies. Valrubicin offers a promising avenue for managing BCG-refractory CIS, providing hope for patients who have exhausted other treatment options. It's like finding a hidden spring in the desert – a source of hope and relief for those seeking a path to recovery.

Dr. Camel's Conclusion

This study provides valuable insights into the efficacy and safety of valrubicin for treating BCG-refractory carcinoma in situ of the bladder. The researchers' findings suggest that valrubicin can be an effective and well-tolerated treatment option for patients who have failed or experienced recurrence after BCG therapy, offering a potential alternative for managing this challenging condition. In the desert of bladder cancer treatment, valrubicin emerges as a promising oasis, providing a glimmer of hope for those seeking a path to recovery.
Date :
  1. Date Completed 2000-03-16
  2. Date Revised 2022-03-30
Further Info :

Pubmed ID

10687972

DOI: Digital Object Identifier

S0022-5347(05)67799-3

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.